tradmap

EDIT Editas Medicine, Inc.

$3.08 +0.00%

Updated

Healthcare · Biological Products, (No Diagnostic Substances)

Editas Medicine, Inc. (EDIT) is a healthcare company in the Biological Products, (No Diagnostic Substances) industry, with a market capitalization of $472 million. Shares last traded at $3.08, 32.1% below their 52-week high. Over the past year the stock is up 23.0%. Net profit margin is -157.3%, below the peer median of 5.3%. Revenue grew 25.4% year over year.

Market Cap
$472M
Shares Out
153.6M
EPS (TTM)
$-4.00
P/E Ratio
P/S Ratio
10.05
P/B Ratio
4.49
Dividend / Share
Dividend Yield
52-Week High
$4.53
52-Week Low
$1.66
Volume
95,993
Avg Vol (3m)
139,107.635

Performance

1W
-6.82%
1M
+11.82%
3M
+3.19%
6M
+62.70%
YTD
+49.27%
1Y
+23.00%

Daily candles · volume · SMA(20)/SMA(50) · Databento EQUS.MINI.

Technicals

RSI (14)
52.55
SMA (50)
$3.00
SMA (200)
$2.61
Price vs SMA50
+2.43%
Price vs SMA200
+17.86%
ATR (14)
$0.21

Full technical analysis (26 indicators, D/W/M) →

Financials

Revenue
$47M
Net Income
$-74M
Gross Margin
Operating Margin
-161.4%
Net Margin
-157.3%
Return on Equity
-70.2%
Return on Assets
-31.2%
Current Ratio
3.19
Debt / Equity
0.46
Revenue Growth (YoY)
+25.4%

Latest reported annual period ending 2026-06-30 · SEC EDGAR/XBRL.

Full financials — revenue, cash flow & debt over time →

Recent earnings

PeriodEPS (diluted)Reported
Q2 2026 $-0.40 2026-08-05
Q1 2026 $-0.26 2026-05-05
FY 2025 $-1.80 2026-03-09
Q3 2025 $-1.80 2025-11-10
Q2 2026 $-1.54 2026-08-05
Q1 2026 $-0.92 2026-05-05

Full earnings history →

Biological Products, (No Diagnostic Substances) peers

EDIT vs 14 industry peers (Biological Products, (No Diagnostic Substances)), by market cap. Updated

P/S vs peers
10.05 / 19.49 med
-48% discount
Net margin vs peers
-157.3% / 5.3% med
below median
1–14 of 14
AMGNAmgen$240.1B27.476.3023.0%+0.31%
GILDGilead Sciences$187.5B-57.876.16-10.6%+1.09%
MRNAModerna$58.8B-18.68-1.94%
RVMDRevolution Medicines, Inc.$45.2B-25.55+0.76%
BIIBBiogen$33.1B24.163.3413.8%+0.78%
NBIXNeurocrine Biosciences Inc$16.1B22.814.7720.9%+0.33%
EXELExelixis, Inc.$14.7B17.036.0235.3%+1.00%
HALOHalozyme Therapeutics, Inc.$12.6B30.397.5524.9%+1.01%
TECHBio-Techne$11.4B62.489.3515.0%+0.21%
KRYSKrystal Biotech, Inc.$11.0B45.5224.9554.8%+0.58%
APGEApogee Therapeutics, Inc.$10.2B-34.57+0.04%
KYMRKymera Therapeutics, Inc.$9.7B-32.51-1.24%
RGENRepligen Corp$9.6B230.5312.205.3%-1.87%
PCVXVaxcyte, Inc.$9.1B-8.56-0.62%

Source: SEC EDGAR (fundamentals/EPS/dividends) · Databento EQUS.MINI (prices) · market cap & yield computed by tradmap. Informational only — not financial advice.